Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 7, 2022- Abbott's Talisman system seals an opening in the heart known as a "patent foramen ovale" (PFO) to prevent blood clots from passing from the right to the left side of the heart and on to the brain, where they can cause a stroke- The Talisman system builds on the Amplatzer PFO Occluder, the world's leading PFO closure device, and comes with the delivery cable pre-attached, making it easier for physicians to use and reducing preparation time
-
Jun 8, 2022- New results demonstrate MitraClip™ transcatheter edge-to-edge repair (TEER) is effective at treating leaky valves in people with secondary mitral regurgitation (MR)- Data from the first report on patients with a pacemaker lead across the tricuspid valve show TriClip™ and TriClip G4 TEER systems significantly reduce tricuspid regurgitation (TR) and substantially improve quality of life
-
Feb 21, 2022- New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS™ HF System, a small implantable sensor that can flag early warning signs of worsening heart failure- FDA approval was supported by data from the GUIDE-HF trial, which suggested that the CardioMEMS sensor can reduce hospitalizations and improve care for more types of patients living with heart failure
- Feb 7, 2022- Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart- Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate- Aveir DR is also specifically designed to be retrieved if therapy needs evolve
- Jan 12, 2022- EnSite™ X EP System with EnSite Omnipolar Technology (OT) provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise
- Nov 12, 2021-- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval
-
Nov 10, 2021- One in four physicians surveyed feel the "lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease" is a key obstacle to an accurate diagnosis- Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described "confusion about what I was supposed to do next" as an important barrier to early and accurate diagnosis- Socioeconomic status, age and gender in underserved communities are contributing factors that impact patients’ access to care
- Sep 30, 2021- Abbott is investing $45 million annually to help identify, treat and prevent malnutrition- Innovation hub will focus on reducing malnutrition for the most vulnerable populations in the world
-
Sep 29, 2021- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide- Abbott’s PFO closure technology helps to prevent blood clots from passing from the right to left side of the heart from where they can travel to the brain and cause a stroke- The Talisman system offers the industry's widest range of device sizes in the U.S. and the occluder comes pre-attached to the delivery cable, making the device easier for physicians to use
-
Sep 28, 2021- People with diabetes who use the FreeStyle Libre mobile app experience clinically significant improved time in target range- Data reinforce the benefits of mobile apps, which can remotely connect people living with diabetes to healthcare professionals during COVID-19- Abbott is joining Novo Nordisk and The diaTribe Foundation in raising awareness and education on Time in Range
-
Sep 22, 2021- New enhancements to Abbott's Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures- Epic Plus designed to help patients with more complex cases of aortic or mitral regurgitation or stenosis- Latest device builds on history of surgical valve replacement as a reliable and critical therapy option for patients with valvular heart disease
- Sep 20, 2021- Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery- With Portico approval, Abbott offers the industry's most comprehensive portfolio of structural heart solutions in the U.S.
- Sep 2, 2021Acquisition builds upon Abbott's leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots
- Aug 30, 2021- New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device- Amulet device is the first and only minimally invasive option approved for LAA occlusion that does not require blood-thinning medication following implantation- Trial results supported recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation
- Aug 27, 2021- The GUIDE-HF study examined the potential impact of Abbott's CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device- Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease
- Aug 16, 2021- Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation- The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with atrial fibrillation, the most common sustained cardiac arrhythmia
- Aug 3, 2021- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence- The new intuitive interface provides step-by-step guidance to enhance ease of use- When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care
Aug 2, 2021- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2]- The FreeStyle Libre 2 app enables kids (ages 4 and older) and adults to easily share their glucose data with parents and other caregivers via the LibreLinkUp[3] app- Free to download on the App Store, the FreeStyle Libre 2 iOS app will be available soon-
Jul 29, 2021- Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott's connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic- Jot Dx™ ICM connects via Bluetooth with Abbott’s myMerlin™ mobile app for continuous remote monitoring, leading to a faster time to diagnosis compared to ICMs that may use traditional bedside monitors1- Abbott’s personalized concierge service, SyncUp™, provides one-on-one device setup support, helping patients connect Jot Dx™ ICM with the mobile app at home, taking the burden off physicians and clinic staff
- Jul 29, 2021- Patients with diabetes who did not meet the recommended daily intake of protein had greater physical limitations, which together may suggest an increased risk of muscle loss- Abbott's line of nutrition products scientifically designed for people with diabetes now includes Glucerna® 30g protein shakes to help people with diabetes meet important daily protein consumption goals
- Jun 30, 2021- New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)- The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval in Europe- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants
-
Jun 7, 2021- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation- New delivery system works with Abbott's leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and seals off a broad range of LAA anatomies- Steerable sheath gives physicians enhanced flexibility and precise placement when implanting Amplatzer Amulet
-
Jun 7, 2021- All 16 Walgreens locations in the city of Philadelphia will provide the rapid BinaxNOW™ COVID-19 Antigen Self Test at no cost to customers who present a Pennsylvania EBT ACCESS Card, starting June 7 and running through July 4- First-of-its-kind pilot program aims to increase consumer access to rapid testing- BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and has been available nationwide for over-the-counter (OTC), non-prescription purchase at Walgreens since mid-April
- May 17, 2021- Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant- The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis
- May 6, 2021- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure- The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats- Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously
-
Apr 26, 2021- New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)- Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment- Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
Apr 12, 2021- Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons- Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games- Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance- Apr 8, 2021- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve- Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy- TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions